Marios Sagris, Stergios Soulaidopoulos, Angelos Papanikolaou, Nikolaos Ktenopoulos, Martijn J H van Oort, Jose M Montero-Cabezas, Nikolaos Patsourakos, Benjamin Honton, Dimitris Tousoulis, Konstantinos Tsioufis
{"title":"Efficacy and Safety of Intravascular Lithotripsy in the Management of Underexpanded Stents: A Systematic Review and Meta-Analysis.","authors":"Marios Sagris, Stergios Soulaidopoulos, Angelos Papanikolaou, Nikolaos Ktenopoulos, Martijn J H van Oort, Jose M Montero-Cabezas, Nikolaos Patsourakos, Benjamin Honton, Dimitris Tousoulis, Konstantinos Tsioufis","doi":"10.1002/ccd.31588","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Stent underexpansion significantly heightens the risk of major adverse cardiac events (MACE), and available treatment options for this condition remain limited. Intravascular Lithotripsy (IVL) technology disrupts superficial and deep calcium by using localized pulsative sonic pressure waves, emerges as a promising tool for underexpanded stents.</p><p><strong>Aims: </strong>This study examines the overall efficacy and safety of IVL, an until-now off-label modality, in the management of underexpanded stents.</p><p><strong>Methods: </strong>Following PRISMA guidelines, we systematically explored PubMed, SCOPUS, and Cochrane databases up to April 30, 2024, for studies evaluating IVL's safety and efficacy in treating underexpanded stents. We gathered angiographic (QCA) and intracoronary imaging (OCT or IVUS) data, examining the stent's diameter stenosis (SDS), minimal lumen diameter (MLD), minimal stent area (MSA), and minimal lumen area (MLA) pre- and post-IVL application. Procedural success constituted the efficacy endpoint, while peri-procedural complications, in-hospital-30-days and long-term mortality, and MACE were safety endpoints.</p><p><strong>Results: </strong>This meta-analysis comprised 23 studies including 819 patients and 837 treated lesions in underexpanded stent. The mean age was 71.7 ± 8.8 years, with an overall IVL procedural success rate of 92% [(95% confidence interval (CI): 88%-95%, I<sup>2</sup> = 35%), while the in-hospital-30-days and long-term mortality incidence were 1% (95% CI: 1%-3%, I<sup>2</sup> = 0%) and 4% (95% CI: 2%-6%, I<sup>2</sup> = 0), respectively. The 30-day rates acute myocardial infarction and stroke were 1% [(95% CI: 0%-1%, I² = 0%), (95% CI: 0%-2%, I<sup>2</sup> = 0%)] each. No need for short term target lesion revascularization (TLR) was observed while the long-term rates were 6% (95% CI: 3%-10%, I<sup>2</sup> = 48%). There was a significant decrease in the SDS [Standardized Mean Difference (SMD): -3.57 (95% CI: -4.64 to -2.44%, I<sup>2</sup> = 94%)] and increase in MSA (SMD: +1.98, 95% CI: 0.86-3.09, I<sup>2</sup> = 93%) after IVL application. It was observed a significant increase in MLD (SMD: +2.68, 95% CI: 1.94-3.41, I<sup>2</sup> = 90%) and in the MLA (SMD: +1.92, 95% CI: 1.46-2.38, I<sup>2</sup> = 69%). Major procedural and device related complications were 2% (95% CI: 1%-5%, I<sup>2</sup> = 0%) and 1% (95% CI: 0%-2%, I<sup>2</sup> = 80%) respectively. Notably low rates were observed for stent thrombosis (1%, 95% CI: 0%-2%, I<sup>2</sup> = 0%), dissections (1%, 95% CI: 1%-4%, I<sup>2</sup> = 0%), perforations (1%, 95% CI: 1%-3%, I<sup>2</sup> = 0%) and no-reflow (0%, 95% CI: 0%-46%, I<sup>2</sup> = 0%).</p><p><strong>Conclusions: </strong>IVL demonstrates promise as a safe and effective strategy for underexpanded stent treatment, characterized by low rates of periprocedural complications. Future prospective studies are now warranted to compare IVL to other lesion preparation strategies.</p>","PeriodicalId":9650,"journal":{"name":"Catheterization and Cardiovascular Interventions","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Catheterization and Cardiovascular Interventions","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ccd.31588","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Stent underexpansion significantly heightens the risk of major adverse cardiac events (MACE), and available treatment options for this condition remain limited. Intravascular Lithotripsy (IVL) technology disrupts superficial and deep calcium by using localized pulsative sonic pressure waves, emerges as a promising tool for underexpanded stents.
Aims: This study examines the overall efficacy and safety of IVL, an until-now off-label modality, in the management of underexpanded stents.
Methods: Following PRISMA guidelines, we systematically explored PubMed, SCOPUS, and Cochrane databases up to April 30, 2024, for studies evaluating IVL's safety and efficacy in treating underexpanded stents. We gathered angiographic (QCA) and intracoronary imaging (OCT or IVUS) data, examining the stent's diameter stenosis (SDS), minimal lumen diameter (MLD), minimal stent area (MSA), and minimal lumen area (MLA) pre- and post-IVL application. Procedural success constituted the efficacy endpoint, while peri-procedural complications, in-hospital-30-days and long-term mortality, and MACE were safety endpoints.
Results: This meta-analysis comprised 23 studies including 819 patients and 837 treated lesions in underexpanded stent. The mean age was 71.7 ± 8.8 years, with an overall IVL procedural success rate of 92% [(95% confidence interval (CI): 88%-95%, I2 = 35%), while the in-hospital-30-days and long-term mortality incidence were 1% (95% CI: 1%-3%, I2 = 0%) and 4% (95% CI: 2%-6%, I2 = 0), respectively. The 30-day rates acute myocardial infarction and stroke were 1% [(95% CI: 0%-1%, I² = 0%), (95% CI: 0%-2%, I2 = 0%)] each. No need for short term target lesion revascularization (TLR) was observed while the long-term rates were 6% (95% CI: 3%-10%, I2 = 48%). There was a significant decrease in the SDS [Standardized Mean Difference (SMD): -3.57 (95% CI: -4.64 to -2.44%, I2 = 94%)] and increase in MSA (SMD: +1.98, 95% CI: 0.86-3.09, I2 = 93%) after IVL application. It was observed a significant increase in MLD (SMD: +2.68, 95% CI: 1.94-3.41, I2 = 90%) and in the MLA (SMD: +1.92, 95% CI: 1.46-2.38, I2 = 69%). Major procedural and device related complications were 2% (95% CI: 1%-5%, I2 = 0%) and 1% (95% CI: 0%-2%, I2 = 80%) respectively. Notably low rates were observed for stent thrombosis (1%, 95% CI: 0%-2%, I2 = 0%), dissections (1%, 95% CI: 1%-4%, I2 = 0%), perforations (1%, 95% CI: 1%-3%, I2 = 0%) and no-reflow (0%, 95% CI: 0%-46%, I2 = 0%).
Conclusions: IVL demonstrates promise as a safe and effective strategy for underexpanded stent treatment, characterized by low rates of periprocedural complications. Future prospective studies are now warranted to compare IVL to other lesion preparation strategies.
期刊介绍：
Catheterization and Cardiovascular Interventions is an international journal covering the broad field of cardiovascular diseases. Subject material includes basic and clinical information that is derived from or related to invasive and interventional coronary or peripheral vascular techniques. The journal focuses on material that will be of immediate practical value to physicians providing patient care in the clinical laboratory setting. To accomplish this, the journal publishes Preliminary Reports and Work In Progress articles that complement the traditional Original Studies, Case Reports, and Comprehensive Reviews. Perspective and insight concerning controversial subjects and evolving technologies are provided regularly through Editorial Commentaries furnished by members of the Editorial Board and other experts. Articles are subject to double-blind peer review and complete editorial evaluation prior to any decision regarding acceptability.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
